$233 Million is the total value of GREAT POINT PARTNERS LLC's 40 reported holdings in Q3 2014. The portfolio turnover from Q2 2014 to Q3 2014 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AUPH | New | AURINIA PHARMACEUTICALS INC | $7,917,000 | – | 2,474,076 | +100.0% | 3.40% | – |
| EXEL | New | EXELIXIS INC | $7,803,000 | – | 5,100,000 | +100.0% | 3.35% | – |
| ADHD | New | ALCOBRA LTDcall | $7,522,000 | – | 487,200 | +100.0% | 3.23% | – |
| ASTM | New | AASTROM BIOSCIENCES INC | $6,185,000 | – | 2,170,000 | +100.0% | 2.66% | – |
| EBS | New | EMERGENT BIOSOLUTIONS INC | $6,180,000 | – | 290,000 | +100.0% | 2.65% | – |
| HTWR | New | HEARTWARE INTL INC | $5,434,000 | – | 70,000 | +100.0% | 2.33% | – |
| TENX | New | TENAX THERAPEUTICS INC | $4,384,000 | – | 1,115,497 | +100.0% | 1.88% | – |
| SNSS | New | SUNESIS PHARMACEUTICALS INCcall | $2,856,000 | – | 400,000 | +100.0% | 1.23% | – |
| CCXI | New | CHEMOCENTRYX INC | $2,177,000 | – | 483,741 | +100.0% | 0.94% | – |
| WGBS | New | WAFERGEN BIO-SYSTEMS INC | $1,834,000 | – | 421,509 | +100.0% | 0.79% | – |
| AMRN | New | AMARIN CORP PLCspons adr new | $1,007,000 | – | 923,534 | +100.0% | 0.43% | – |
| ADHD | New | ALCOBRA LTDput | $559,000 | – | 36,200 | +100.0% | 0.24% | – |
| ZFGN | New | ZAFGEN INC | $331,000 | – | 16,855 | +100.0% | 0.14% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-06-05 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.